Personal care services

Payments-attached and well funded, with Fresha competing at zero subscription cost by monetising payments alone — a free-alternative problem in a vertical market rather than a horizontal one. Nothing is disclosed here. Every vendor named on this record is private, or sits inside a parent that does not break the line out, so no revenue floor can be built and the market size is genuinely unknown rather than estimated.

Medspas straddle two codes. They are filed here under 812190 (other personal care services), but the injecting, prescribing and supervising happen under a medical director, which is physicians'-office work (621111). The software follows that split. How this differs from salon and spa software (812115): the salon stack is booking, staff, retail and payments. A medspa needs all of that plus a clinical record. That means injectable charting on a face map with units, product and lot numbers; signed treatment consents; before-and-after photos; good-faith exams and medical-director sign-off; e-prescribing; and memberships and loyalty programs that sell treatment packages ahead of time. The customer is also different. AmSpa counted 10,488 US medspas in 2023, up from 8,899, averaging about $1.4M in revenue each; 81% are single-location, and 67% of single-owner practices are owned by non-physicians [B, association survey]. That is a larger ticket than a salon, and the owner carries medical liability. There is no single incumbent; two camps meet in the middle. On the clinical side, PatientNow (owned by PSG; 5,000+ locations claimed), Aesthetic Record (9,000+ clinics claimed) and AestheticsPro (claims nearly 30% of US and Canadian medspas) sell an aesthetics EMR with booking attached. Nextech, which TPG bought for $1.4B in 2023 [B], covers the surgeon and dermatologist end. On the salon-platform side, Boulevard ($80M Series D led by JMI Equity, July 2025, about $800M valuation, about $188M raised) says medspas are its fastest-growing segment and that it powers about 15% of US medspas [B; share C]. Zenoti (about $331M raised, valued near $1.5B in 2021) [B] and Mangomint (about $48M) [B] sell medspa editions of their salon software. The vendor claims add up to more clinics than AmSpa counts, so the shares overlap or are inflated. The obvious wedges are already funded. Moxie ($51M total; $25M Series C led by Viewpoint Ventures, March 2026) [B] bundles EMR, compliance, medical-director matching and coaching for a share of practice sales, which is closer to a franchise or management company than to SaaS. RepeatMD ($50M Series A including $10M of debt, co-led by Centana Growth Partners and Full In Partners, November 2023) [B] owns memberships, rewards and e-commerce as an add-on that plugs into the EMRs. PatientNow bought Recura (an AI receptionist) in November 2025 [B]. A new entrant would face PE-owned EMRs, three venture-funded booking platforms that already process medspa payments, and funded specialists in the two places a newcomer would start: compliance and memberships. Incumbent vulnerability decides it. No vendor publishes revenue.